822 A1A NORTH, PONTE VEDRA, FL
Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
Annual Report to Security Holders
Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
Chief Medical Officer Departure - James J. Ferguson Resigns
CMO Departure - James J. Ferguson III Resigns from Cadrenal Therapeutics
Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
CFO Appointment - John P. Sharp Named Interim Chief Financial Officer
To File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
Q2
Q1
FY 2025
Q3
FY 2024
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Notice of Exempt Offering of Securities
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement